The Startup Behind The Pill For Sleep Apnea Raises $192 Million In IPO

Even earlier it gets approval for its slumber apnea pill, Apnimed is testing investor appetite.

The Cambridge, Mass.-based biotech priced its shares astatine $16 to raise $192 cardinal successful an upsized IPO that would worth the institution astatine much than $600 million. The company’s banal is group to statesman trading connected Friday connected Nasdaq.

“It’s been a one-size, fits-all disease, treated pinch a one-size, fits-all machine,” CEO Kevin Lind, 50, tells Forbes. “There is simply a amended way.”

Lind took complete arsenic CEO from cofounder Larry Miller, a pulmonary expert and serial entrepreneur who had postponed his ain status to motorboat the company, successful June. Lind, the company’s erstwhile committee chairman, had antecedently cofounded Longboard Pharmaceuticals, which developed an epilepsy supplier and was acquired by Denmark’s Lundbeck for $2.6 cardinal successful 2024. Miller, 73, remains connected the committee arsenic vice chairman.

Forbes profiled the company and its efforts to create a supplier for slumber apnea, a information that affects arsenic galore arsenic 80 cardinal group successful the U.S. alone, earlier this year.

Researchers person been trying without occurrence for decades to create a supplier that could hole slumber apnea, a communal information successful which breathing pauses during sleep, sometimes lowering oxygen levels to a vulnerable degree. Today, the superior curen for the illness is simply a continuous affirmative airway unit machine, known arsenic a CPAP, which forces aerial down the wearer’s pharynx to support it open. The instrumentality works, but nary surprise, it’s hated by astir everyone who has to usage it. Many group pinch slumber apnea garbage to effort it aliases won’t moreover get diagnosed for fearfulness they whitethorn person to.

Lind says that only 23 cardinal group – a number of those pinch the illness – person been officially diagnosed, and of those 10.5 cardinal stay untreated. “This gives america a tremendous opportunity to turn the market,” he says. “The easiest spot for america to commencement is pinch the 10.5 cardinal who are diagnosed and person chosen not to beryllium treated.”

Research shows that group pinch untreated slumber apnea are much apt to create bosom trouble, strokes and possibly moreover Parkinson’s and Alzheimer’s. A curen that’s easier for patients to carnivore could person a transformative effect connected their wide health.

That’s why erstwhile Harvard interrogator Dr. Luigi Taranto Monetemurro, now Apnimed’s main technological officer, was testing a imaginable apnea medicine backmost successful November 2016, he was shocked to observe it was helping his taxable respire normally. Apnimed launched successful 2017 aft acquiring authorities to that imaginable therapy.

The institution raised immoderate $260 cardinal from investors that see Morningside Group, Alpha Wave Global and Sectoral Asset Management astatine a valuation of astir $400 million. Its early believers guidelines to make a bundle connected the IPO.

“The easiest spot for america to commencement is pinch the 10.5 cardinal who are diagnosed and person chosen not to beryllium treated.”

Until recently, slumber medicine had been thing of a backwater, but that whitethorn beryllium changing. At the extremity of 2024, the FDA approved Eli Lilly’s weight-loss supplier Zepbound for the curen of moderate-to-severe slumber apnea successful adults who are obese. Unlike Apnimed’s pill, Zepbound does not dainty slumber apnea directly, but useful indirectly because group who are overweight are much apt to suffer from it. “People thin to judge that OSA [sleep apnea] is associated pinch obesity, but complete 60% of the patients pinch it are not obese,” Lind says.

Last year, Apnimed reported a $58 cardinal nett nonaccomplishment from continuing operations connected gross of conscionable $38 million, according to its prospectus. In March, the institution sold its 50% liking successful a associated task pinch Japanese biotech Shionogi related to different imaginable slumber apnea therapy to that patient for $100 cardinal upfront, positive a $50 cardinal milestone payment, and royalties, successful bid to attraction connected its ain pill.

The large mobility now is the commercialized trajectory for Apnimed’s first slumber apnea drug, a once-nightly pill. The institution submitted the medicine to the FDA for support and could person the okay successful the first 4th of 2027. Lind says Apnimed has not yet group the value for the pill, but has begun preparations for its commercialized launch. Even if a mini percent of group pinch slumber apnea were to return its pill, the supplier would apt go a blockbuster. “The numbers are staggering,” Miller told Forbes last winter.

MORE FROM FORBES

ForbesA 'Holy Grail' Sleep Apnea Pill Could Be On The Market Next YearBy Amy FeldmanForbesHow OpenAI Plans To Win Over Doctors, Patients And HospitalsBy Amy Feldman and Rashi ShrivastavaForbesPeptides May Soon Be Legal. These Companies Are Ready To Cash InBy Amy FeldmanForbesWhy Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery StartupBy Amy FeldmanForbesThe Startup Using AI To Make Hearing Aids BetterBy Amy Feldman and Alex Knapp